| Přispěvatelé: |
De Berardis, D., Serroni, N., Olivieri, L., Gianfelice, D., Iasevoli, F., Tomasetti, C., de Batolomeis, A., Mazza, M., Valchera, A., Fornaro, M., Di Fabio, F., Cavedini, P., Perna, G., Piersanti, M., Di Nicola, M., Odorisio, M., Carano, A., Vellante, Sergio, Matarazzo, I., Di Giannantonio, M. |
| Popis: |
Schizophrenia is a chronic and disabling disorder, characterized by positive, negative, cognitive and affective symptoms. The first episode of schizophrenia (FES) usually occurs after a variable period of prodromic symptoms and the importance of early detection and treatment of FES has been raised in psychiatric literature from long time. In fact, it has been suggested that the first years of the schizophrenic disorder may be a critical period for long-term prognosis, as the relationship between the poor medication adherence and poorer outcome is well demonstrated. Longacting injectable formulations of second-generation antipsychotics (SGAs-LAIs) provide constant medication delivery and the potential for improved adherence. Currently, four SGAs-LAIs are available for the treatment of schizophrenia, risperidone long-acting injectable, olanzapine pamoate, paliperidone palmitate and aripiprazole. Several studies have also demonstrated efficacy and safety of such drugs in patients with schizophrenia. In the present paper the literature on SGAs-LAIs atypical antipsychotics in the treatment of FES will be reviewed and practical advice will be given concerning the use of this drug in the everyday clinical practice. |
